CDEK
← All drugs Report issue

poziotinib

Small moleculeexperimental

Poziotinib is a drug in development by Hanmi Pharmaceutical, Luye Pharma (China), and Spectrum Pharmaceuticals for various cancers. — Wikipedia

Clinical trial activity

24 trials · 17 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
18
Phase 3
1
Phase 4
0

Earliest trial started Nov 1, 2009 (NCT01455571)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1
Mol. weight
491.35 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • hm781-36
  • hm-781-36b
  • hm-781-36b
  • hm781-36b
  • hm781-36b
  • hm781-36b
  • nov-120101
  • nov-120101
  • poziotinib
  • poziotinib
  • poziotinib
  • poziotinib
  • poziotinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05378763Phase 3May 12, 2022Spectrum Pharmaceuticals
NCT05045404Phase 2Dec 30, 2021University of Texas at Houston
NCT04981704Phase 1Apr 8, 2021Spectrum Pharmaceuticals
NCT04402008Phase 1/Phase 2 (Phase 2)Jun 30, 2020Spectrum Pharmaceuticals
NCT04436562Phase 1May 29, 2020Spectrum Pharmaceuticals
NCT04172597Phase 2Dec 31, 2019Spectrum Pharmaceuticals
NCT04044170Phase 2Jul 30, 2019Hanmi Pharmaceutical
NCT03770988Phase 2Apr 1, 2019Yonsei University
NCT03804515Phase 1Mar 31, 2019Spectrum Pharmaceuticals
NCT03744715Phase 2Oct 5, 2018Spectrum Pharmaceuticals
NCT03429101Phase 1May 31, 2018Spectrum Pharmaceuticals
NCT03318939Phase 2Oct 13, 2017Spectrum Pharmaceuticals
NCT03292250Phase 2Sep 10, 2017Chungnam National University, Seoul National University
NCT03066206Phase 2Mar 17, 2017Lung Cancer Research Foundation, Spectrum Pharmaceuticals, University of Texas at Houston
NCT02659514Phase 2Feb 1, 2016Spectrum Pharmaceuticals
NCT02979821Phase 2Oct 1, 2015Chonnam National University, Chungnam National University, Konkuk University, Korean Association for the Study of Targeted Therapy, Kosin University, Kyungpook University
NCT02544997Phase 2Sep 1, 2015Sungkyunkwan University
NCT02418689Phase 2Mar 1, 2015Hanmi Pharmaceutical, National OncoVenture
NCT02216916Phase 2Aug 1, 2014Yonsei University
NCT01819428Phase 2Mar 1, 2013Hanmi Pharmaceutical, National OncoVenture
Showing 20 of 24 trials
Page 1 / 2

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Spectrum PharmaceuticalsFor profit111032016
Hanmi PharmaceuticalFor profit7422009
National OncoVentureAcademic/Hospital4312012
Chungnam National UniversityAcademic/Hospital2012015
Seoul National UniversityAcademic/Hospital2122009
University of Texas at HoustonAcademic/Hospital2212017
Yonsei UniversityAcademic/Hospital2212014
Chonnam National UniversityAcademic/Hospital1012015
Chungbuk National UniversityAcademic/Hospital1012013
Gachon UniversityAcademic/Hospital1012013
Konkuk UniversityAcademic/Hospital1012015
Korean Association for the Study of Targeted TherapyAcademic/Hospital1112015
Kosin UniversityAcademic/Hospital1012015
Kyungpook UniversityAcademic/Hospital1012015
Lung Cancer Research FoundationAcademic/Hospital1012017
Sungkyunkwan UniversityAcademic/Hospital1112015
University of UlsanAcademic/Hospital1012013
17 organizations
Page 1 / 1